Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

2011 ◽  
Vol 45 (3) ◽  
pp. 129-134 ◽  
Author(s):  
Raimondo Forte ◽  
Paola Bonavolontà ◽  
Yohan Benayoun ◽  
Jean Paul Adenis ◽  
Pierre-Yves Robert
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Verteporfin Therapy ◽  
Age Related

Can Intravitreal Ranibizumab Alter Retrobulbar Circulation in Eyes with Age-Related Macular Degeneration?

2013 ◽  
Vol 29 (8) ◽  
pp. 723-727 ◽  
Author(s):  
Kemal Yuksel ◽  
Hasan Altinkaynak ◽  
Adnan Kina ◽  
Necip Kara ◽  
Ahmet Taylan Yazici ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]

2016 ◽  
pp. 775
Author(s):  
Katarzyna Michalska-Malecka ◽  
Adam Kabiesz ◽  
Małgorzata Kimsa ◽  
Barbara Strzałka-Mrozik ◽  
Maria Formińska-Kapuścik ◽  
...  
Keyword(s):  
Gene Expression ◽  
Macular Degeneration ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up

2015 ◽  
Vol 234 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Wataru Matsumiya ◽  
Shigeru Honda ◽  
Keiko Otsuka ◽  
Akiko Miki ◽  
Takayuki Nagai ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Morphological Parameters ◽  
Intravitreal Ranibizumab ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
The Mean ◽  
Choroidal Vasculopathy

Purpose: To compare the response to ranibizumab between patients with typical neovascular age-related macular degeneration (tAMD) and those with polypoidal choroidal vasculopathy (PCV), and to determine the predictors for the outcomes. Methods: Fifty-nine eyes from 59 consecutive patients (tAMD: 27 eyes, PCV: 32 eyes) were treated with three monthly ranibizumab injections followed by as-needed retreatment. Best-corrected visual acuity (BCVA) and morphological parameters were evaluated over 24 months of follow-up. Results: The mean BCVA in tAMD and PCV patients was significantly improved at 3 months (-0.22 and -0.09 logMAR units, respectively). The improvement in BCVA was sustained up to 24 months in tAMD (p = 0.01) but not in PCV patients. The significant predictor for good response to ranibizumab in tAMD patients was the improvement of BCVA at 3 months, whereas that in PCV patients was the anatomical resolution at 3 months. Conclusions: Ranibizumab is an effective therapy for tAMD and PCV over 24 months. The predictors for good outcome might be different between tAMD and PCV.

Sign in / Sign up

Export Citation Format

Share Document